Komori
Kissei Pharmaceutical (4547) · RiskRestated

Litigation Risk Associated with Domestic and Overseas Business Activities

First written in FY2016. 19 of 21 entries say "Restated". Latest entry: FY2024.

21entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2020-Q3RestatedFY2021-Q1 – FY20242016: 120162017: 220172018: 320182019: 420192020: 420202021: 120212022: 320222023: 220232024: 12024
Same theme, other companies
Litigation and Litigation-Related Loss RiskA theme 300 companies write about · 302 as a headwind · 0 as a tailwind

110 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 302 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024RestatedAnnual report

    「Although no lawsuits that could affect the management of our group are currently pending, as our group continues its business activities in Japan and overseas, it may face lawsuits relating to patents, product liability, environmental matters, labor matters, fair trade, and other issues.」

    While stating that no material lawsuits have been filed, the possibility of litigation arising from business activities in Japan and overseas has been reconfirmed.
  2. FY2024-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  3. FY2023-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  4. FY2023-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  5. FY2023-Q1RestatedAnnual report

    「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  6. FY2022-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  7. FY2022-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  8. FY2021-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  9. FY2021-Q1RestatedAnnual report

    「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  10. FY2020WorsenedAnnual report

    「Although no lawsuits that could affect the management of our group are currently pending, as our group continues its business activities in Japan and overseas, it may face lawsuits relating to patents, product liability, environmental matters, labor matters, fair trade, and other issues.」

    Fair-trade-related matters have been added to the previously identified litigation risks, expanding the scope of covered areas.
  11. FY2020-Q3RestatedAnnual report

    「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  12. FY2020-Q2RestatedAnnual report

    「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  13. FY2020-Q1RestatedAnnual report

    「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  14. FY2019RestatedAnnual report

    「Although no lawsuits that could affect the management of our group are currently pending, as our group continues its business activities in Japan and overseas, it may face lawsuits relating to patents, product liability, environmental matters, labor matters, and other issues.」

    While stating that no material lawsuits are pending, the possibility of future litigation arising from business activities in Japan and overseas has been reconfirmed.
  15. FY2019-Q3RestatedAnnual report

    「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  16. FY2019-Q2RestatedAnnual report

    「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  17. FY2018RestatedAnnual report

    「Although no lawsuits that could affect the management of our group are currently pending, as our group continues its business activities in Japan and overseas, it may face lawsuits relating to patents, product liability, environmental matters, labor matters, and other issues.」

    While stating that no material lawsuits are pending, the possibility of future litigation arising from business activities in Japan and overseas has been reconfirmed.
  18. FY2018-Q3RestatedAnnual report

    「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  19. FY2018-Q2RestatedAnnual report

    「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of litigation arising from business activities in Japan and overseas.
  20. FY2017RestatedAnnual report

    「Although no lawsuits that could affect the management of our group are currently pending, as our group continues its business activities in Japan and overseas, it may face lawsuits relating to patents, product liability, environmental matters, labor matters, and other issues.」

    While stating that there are currently no material lawsuits, the possibility of future litigation arising from business activities in Japan and overseas has been reconfirmed.
  21. FY2016First statedAnnual report

    「Although no lawsuits that could affect the management of our group are currently pending, as our group continues its business activities in Japan and overseas, it may face lawsuits relating to patents, product liability, environmental matters, labor matters, and other issues.」

    While stating that there are currently no lawsuits affecting management, the possibility of future litigation in multiple areas is documented.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Kissei Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Litigation Risk Associated with Domestic and Overseas Business Activities | KISSEI PHARMACEUTICAL CO.,LTD. (4547) | Komori